PMID- 27826532
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200930
IS  - 2218-6751 (Print)
IS  - 2226-4477 (Electronic)
IS  - 2218-6751 (Linking)
VI  - 5
IP  - 5
DP  - 2016 Oct
TI  - KRAS mutations in the circulating free DNA (cfDNA) of non-small cell lung cancer 
      (NSCLC) patients.
PG  - 511-516
AB  - Circulating free DNA (cfDNA) is obtained from serum or plasma by non-invasive 
      methods such as a simple blood draw, a technique known as "liquid biopsy". 
      Genetic analyses of driver alterations in cfDNA have proved very effective to 
      predict survival and treatment response of cancer patients according to tumoral 
      cfDNA burden in blood. Non-small cell lung cancer (NSCLC) patients with higher 
      concentration of tumoral cfDNA in blood have, on average, shorter 
      progression-free survival (PFS) and overall survival (OS). Regarding specific 
      genetic alterations, KRAS proto-oncogene, GTPase (KRAS) is one of the main genes 
      involved in NSCLC and several studies have been performed to determine its value 
      as a predictive and prognostic biomarker in liquid biopsy. Unfortunately, to date 
      no strong conclusions can be drawn since they have yielded contradictory results. 
      Therefore, further investigations are necessary to establish the value of KRAS 
      testing in liquid biopsy as prognostic or predictive factor in NSCLC. Herein, we 
      review the current knowledge on the importance of KRAS as prognostic and 
      predictive biomarker using non-invasive approaches and the scientific data 
      available regarding its application in clinical practice for treatment of NSCLC.
FAU - Garzon, Monica
AU  - Garzon M
AD  - Pangaea Biotech, Laboratory of Oncology, Quiron Dexeus University Hospital, 08028 
      Barcelona, Spain.
FAU - Villatoro, Sergi
AU  - Villatoro S
AD  - Pangaea Biotech, Laboratory of Oncology, Quiron Dexeus University Hospital, 08028 
      Barcelona, Spain.
FAU - Teixido, Cristina
AU  - Teixido C
AD  - Pangaea Biotech, Laboratory of Oncology, Quiron Dexeus University Hospital, 08028 
      Barcelona, Spain.
FAU - Mayo, Clara
AU  - Mayo C
AD  - Pangaea Biotech, Laboratory of Oncology, Quiron Dexeus University Hospital, 08028 
      Barcelona, Spain.
FAU - Martinez, Alejandro
AU  - Martinez A
AD  - Dr Rosell Oncology Institute, Quiron Dexeus University Hospital, 08028 Barcelona, 
      Spain.
FAU - de Los Llanos Gil, Maria
AU  - de Los Llanos Gil M
AD  - Dr Rosell Oncology Institute, Quiron Dexeus University Hospital, 08028 Barcelona, 
      Spain.
FAU - Viteri, Santiago
AU  - Viteri S
AD  - Dr Rosell Oncology Institute, Quiron Dexeus University Hospital, 08028 Barcelona, 
      Spain.
FAU - Morales-Espinosa, Daniela
AU  - Morales-Espinosa D
AD  - Dr Rosell Oncology Institute, Quiron Dexeus University Hospital, 08028 Barcelona, 
      Spain.
FAU - Rosell, Rafael
AU  - Rosell R
AD  - Pangaea Biotech, Laboratory of Oncology, Quiron Dexeus University Hospital, 08028 
      Barcelona, Spain;; Dr Rosell Oncology Institute, Quiron Dexeus University 
      Hospital, 08028 Barcelona, Spain;; Cancer Biology & Precision Medicine Program, 
      Catalan Institute of Oncology, Germans Trias i Pujol Health Sciences Institute 
      and Hospital, Crta de Canyet s/n, 08016 Badalona, Spain;; Autonomous University 
      of Barcelona (UAB), Campus Can Ruti, Crta de Canyet s/n, 08016 Badalona, Spain;; 
      Molecular Oncology Research (MORe) Foundation, 08028 Barcelona, Spain.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - China
TA  - Transl Lung Cancer Res
JT  - Translational lung cancer research
JID - 101646875
PMC - PMC5099515
OTO - NOTNLM
OT  - KRAS
OT  - Liquid biopsy
OT  - circulating free DNA (cfDNA)
OT  - lung cancer
OT  - non-small cell lung cancer (NSCLC)
COIS- The authors have no conflicts of interest to declare.
EDAT- 2016/11/09 06:00
MHDA- 2016/11/09 06:01
PMCR- 2016/10/01
CRDT- 2016/11/10 06:00
PHST- 2016/11/10 06:00 [entrez]
PHST- 2016/11/09 06:00 [pubmed]
PHST- 2016/11/09 06:01 [medline]
PHST- 2016/10/01 00:00 [pmc-release]
AID - tlcr-05-05-511 [pii]
AID - 10.21037/tlcr.2016.10.14 [doi]
PST - ppublish
SO  - Transl Lung Cancer Res. 2016 Oct;5(5):511-516. doi: 10.21037/tlcr.2016.10.14.